RxDoctor Payments Data

Larhoda Chavis, MD

Internal Medicine · Oxford, NCNPI 1437151784

Payments from drug & device makers

$729in general payments, 2019–2025

Across 51 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$162
  • Amgen$99
  • AstraZeneca$78
  • Merck$53
  • E.r. Squibb & Sons, L.L.C.$45
  • Amarin Pharma, Inc.$44
  • plus $248 from 10 others

What the payments were for

  • Food & beverage$71498%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$729 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,085
Medicare patients
75
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$75,809
OzempicSemaglutide61$75,187
JardianceEmpagliflozin96$74,039
LinzessLinaclotide79$52,506
JanuviaSitagliptin Phosphate77$47,048
RybelsusSemaglutide42$46,804
TradjentaLinagliptin46$43,573
FarxigaDapagliflozin Propanediol45$38,191
TrulicityDulaglutide23$33,160
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$24,192
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog46$21,874
Tresiba Flextouch U-200Insulin Degludec28$18,411
Breo ElliptaFluticasone/Vilanterol28$13,806
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro46$10,555
Lantus SolostarInsulin Glargine,hum.Rec.Anlog99$9,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$162$121,991103 claims
PfizerEliquis, Premarin$40$79,295127 claims
AbbVieLinzess, Namzaric, Synthroid$33$62,100128 claims
MerckJanuvia$53$47,04877 claims
Lilly USA, LLCTrulicity, Cymbalta$12$39,52534 claims
AstraZenecaFarxiga$78$38,19145 claims
Johnson & JohnsonXarelto$35$6,78612 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$41$6,76512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Oxford

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →